In this free webinar, learn about parameters that limit the efficacy of current chimeric antigen receptor (CAR) T-cell therapies and enable the development of CAR T-cells with enhanced performance.

A study at MedUni Vienna's Department of Dermatology provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and describes their different immunomodulatory ...

Distinct subtypes with different roles in the tumor microenvironment Two of these subtypes have ... They surround the tumor ...

A study at MedUni Vienna's Department of Dermatology provides insights into the diversity of cancer-associated fibroblasts in ...

New research provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Annual BioTech Breakthrough Award is devoted to honoring excellence in life science and biotechnology solutions, services, ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in ...

Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but ...

The Centenary Institute has received important funding from the RT Hall Trust to bolster two ground-breaking cancer research initiatives. Almost one ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...